The Gulf Time Newspaper One of the finest business newspapers in the UAE brought to you by our professional writers and editors.
ABU DHABI/WAM
The Abu Dhabi Health Services Company (SEHA), a subsidiary of PureHealth, has successfully treated a 54-year-old patient with End-Stage Renal Disease (ESRD) undergoing dialysis for thyroid cancer using radioactive treatment.
This marks a significant breakthrough in administering radioactive iodine therapy to a patient in need of hemodialysis (HD) during isolation, setting a new precedent for innovative, collaborative and safe healthcare practices.
The operation was a collaborative effort by specialists from SEHA’s Sheikh Khalifa Medical City (SKMC) and SEHA Kidney Care (SKC), bringing together experts in Nuclear Medicine, Endocrinology, Kidney Care, Dialysis services, Environmental Health & Safety, and engineering.
This multidisciplinary approach was essential for addressing the unique challenges faced by the patient’s condition.
Radioactive iodine therapy, a cornerstone treatment for thyroid cancer post-surgery, requires precise dosing based on patient risk stratification.
The decision for the patient to undergo a Total Thyroidectomy followed by postoperative radioactive iodine therapy was unanimously agreed upon by the Thyroid Cancer Multidisciplinary Team. This choice aimed to effectively remove and treat thyroid cancer, with a particular focus on ensuring the safety and efficacy of dialysis during the patient’s period of radioactive isolation.